Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million

Reuters

11/07

<a href="https://laohu8.com/S/ORGO">Organogenesis Holdings Inc</a>. reports third quarter net product revenue of $150.5 million

Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581048698"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581048698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581048698?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581048698","market":"us","top_or_hot":-1,"title":"Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ORGO\">Organogenesis Holdings Inc</a>. reports third quarter net product revenue of $150.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ORGO\">Organogenesis Holdings Inc</a>. reports third quarter net product revenue of $150.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORGO","symbol_name":"Organogenesis Holdings Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4rVz6n:1","article_id":"2581048698","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581048698","pubTimestamp":1762463836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORGO":"Organogenesis Holdings Inc","BK4139":"生物科技"},"translate_title":"Organogenesis Holdings Inc.报告第三季度产品净收入为1.505亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":0.9},"content_text":"Organogenesis Holdings Inc. reports third quarter net product revenue of $150.5 million\n    \n\n        Organogenesis Holdings Inc. reported third quarter 2025 net product revenue of $150.5 million, a 30.6% increase from $115.2 million in the same period of 2024. Net product revenue from Advanced Wound Care products reached $141.5 million, up 31% year over year. Net income for the quarter ranged between $8.6 million and $25.4 million, while adjusted net income was between $21.5 million and $38.4 million. EBITDA was between $19.1 million and $41.9 million, and adjusted EBITDA ranged from $45.5 million to $68.3 million. The company attributed the record revenue to execution of its strategy and highlighted positioning for 2026 in light of the new CMS payment rule and the potential of its ReNu product in a new market opportunity.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}